✦ LIBER ✦

Drug discovery approaches targeting the PI3K/Akt pathway in cancer

✍ Scribed by Garcia-Echeverria, C; Sellers, W R

Book ID: 109970571
Publisher: Nature Publishing Group
Year: 2008
Tongue: English
Weight: 343 KB
Volume: 27
Category: Article
ISSN: 0950-9232
DOI: 10.1038/onc.2008.246

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Exploiting the PI3K/AKT Pathway for Canc

Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery

✍ Hennessy, Bryan T.; Smith, Debra L.; Ram, Prahlad T.; Lu, Yiling; Mills, Gordon 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 472 KB

The Akt/PKB pathway: molecular target fo

The Akt/PKB pathway: molecular target for cancer drug discovery

✍ Cheng, Jin Q; Lindsley, Craig W; Cheng, George Z; Yang, Hua; Nicosia, Santo V 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 271 KB

Expanding therapeutic targets in bladder

Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway

✍ Ching, Christina Barbara; Hansel, Donna Elizabeth 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 216 KB

Inhibiting the PI3K/Akt pathway reversed

Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer

✍ Chao Gu; Zhenbo Zhang; Yinhua Yu; Yingtao Liu; Fengdi Zhao; Lianhua Yin; Youji F 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 601 KB

The PI3K/AKT/mTOR Signaling Pathway: Imp

The PI3K/AKT/mTOR Signaling Pathway: Implications in the Treatment of Breast Cancer

✍ Eleni Andreopoulou 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 278 KB

FGFR1/PI3K/AKT signaling pathway is a no

FGFR1/PI3K/AKT signaling pathway is a novel target for antiangiogenic effects of the cancer drug Fumagillin (TNP-470)

✍ Gregory J. Chen; Brian Weylie; Chen Hu; James Zhu; Reza Forough 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 279 KB 👁 1 views

## Abstract Fibroblast growth factor‐1 (FGF1), a prototypic member of the FGF family, is a potent angiogenic factor. Although FGF‐stimulated angiogenesis has been extensively studied, the molecular mechanisms regulating FGF1‐induced angiogenesis are poorly understood in vivo. Fumagillin, an antiang